Celon Pharma S.A.

WSE:CLN Stock Report

Market Cap: zł1.1b

Celon Pharma Valuation

Is CLN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of CLN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: CLN (PLN20.5) is trading below our estimate of future cash flow value (PLN66.91)

Significantly Below Future Cash Flow Value: CLN is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CLN?

Key metric: As CLN is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for CLN. This is calculated by dividing CLN's market cap by their current revenue.
What is CLN's PS Ratio?
PS Ratio4.9x
Saleszł225.60m
Market Capzł1.10b

Price to Sales Ratio vs Peers

How does CLN's PS Ratio compare to its peers?

The above table shows the PS ratio for CLN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average7.4x
MOC Molecure
17.8xn/azł115.8m
BGD Biogened
0.4xn/azł45.7m
GRZ Green Zebras Spolka Akcyjna
9.9xn/azł12.7m
SLV Selvita
1.5x11.12%zł549.7m
CLN Celon Pharma
4.9x7.79%zł1.1b

Price-To-Sales vs Peers: CLN is good value based on its Price-To-Sales Ratio (4.9x) compared to the peer average (7.4x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does CLN's PS Ratio compare vs other companies in the European Pharmaceuticals Industry?

27 CompaniesPrice / SalesEstimated GrowthMarket Cap
CLN 4.9xIndustry Avg. 4.0xNo. of Companies34PS0612182430+
27 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: CLN is expensive based on its Price-To-Sales Ratio (4.9x) compared to the European Pharmaceuticals industry average (4x).

Price to Sales Ratio vs Fair Ratio

What is CLN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CLN PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio4.9x
Fair PS Ratio7x

Price-To-Sales vs Fair Ratio: CLN is good value based on its Price-To-Sales Ratio (4.9x) compared to the estimated Fair Price-To-Sales Ratio (7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CLN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentzł20.50
zł20.44
-0.29%
15.95%zł25.50zł16.00n/a5
May ’27zł21.25
zł20.44
-3.81%
15.95%zł25.50zł16.00n/a5
Apr ’27zł20.30
zł21.92
+7.98%
26.75%zł32.90zł16.00n/a5
Mar ’27zł22.70
zł22.84
+0.62%
26.76%zł32.90zł16.00n/a5
Feb ’27zł21.80
zł22.84
+4.77%
26.76%zł32.90zł16.00n/a5
Jan ’27zł20.35
zł24.24
+19.12%
26.11%zł32.90zł16.00n/a5
Dec ’26zł21.60
zł24.24
+12.22%
26.11%zł32.90zł16.00n/a5
Nov ’26zł21.55
zł27.44
+27.33%
23.35%zł34.00zł16.00n/a5
Oct ’26zł22.10
zł27.44
+24.16%
23.35%zł34.00zł16.00n/a5
Sep ’26zł22.75
zł27.44
+20.62%
23.35%zł34.00zł16.00n/a5
Aug ’26zł23.10
zł27.44
+18.79%
23.35%zł34.00zł16.00n/a5
Jul ’26zł22.90
zł26.64
+16.33%
29.54%zł34.00zł12.00n/a5
Jun ’26zł22.00
zł27.64
+25.64%
32.49%zł39.00zł12.00zł20.505
May ’26zł25.75
zł27.64
+7.34%
32.49%zł39.00zł12.00zł21.255
Apr ’26zł26.70
zł27.64
+3.52%
32.49%zł39.00zł12.00zł20.305
Mar ’26zł23.65
zł27.64
+16.87%
32.49%zł39.00zł12.00zł22.705
Feb ’26zł24.20
zł27.64
+14.21%
32.49%zł39.00zł12.00zł21.805
Jan ’26zł26.45
zł27.64
+4.50%
32.49%zł39.00zł12.00zł20.355
Dec ’25zł26.95
zł25.58
-5.08%
39.70%zł39.00zł12.00zł21.605
Nov ’25zł27.80
zł26.38
-5.11%
39.69%zł39.00zł12.00zł21.555
Oct ’25zł27.45
zł26.38
-3.90%
39.69%zł39.00zł12.00zł22.105
Sep ’25zł31.70
zł21.10
-33.44%
45.67%zł39.00zł12.00zł22.755
Aug ’25zł26.60
zł21.10
-20.68%
45.67%zł39.00zł12.00zł23.105
Jul ’25zł15.80
zł16.78
+6.20%
21.19%zł23.00zł12.00zł22.905
Jun ’25zł15.58
zł16.78
+7.70%
21.19%zł23.00zł12.00zł22.005
zł20.44
Fair Value
0.3% overvalued intrinsic discount
5
Number of Analysts

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/01 07:58
End of Day Share Price 2026/05/29 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Celon Pharma S.A. is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Beata Szparaga-WasniewskaBiuro maklerskie mBanku
Tomasz SokolowskiErste Bank Polska S.A.
Piotr ZielonkaErste Bank Polska S.A.